Circulating IL-6 and not its circulating signaling components sIL-6R and sgp130 demonstrate clinical significance in NSCLC patients treated with immune checkpoint inhibitors by Yoshiro Nakahara, Yoshiro Nakahara, Taku Kouro, Taku Kouro, Satoru Motoyama, Satoru Motoyama, Satoru Motoyama, Masatomo Miura, Kazuma Fujita, Yuka Igarashi, Naoko Higashijima, Norikazu Matsuo, Hidetomo Himuro, Hidetomo Himuro, Feifei Wei, Feifei Wei, Shun Horaguchi, Shun Horaguchi, Shun Horaguchi, Kayoko Tsuji, Kayoko Tsuji, Yasunobu Mano, Yasunobu Mano, Mitsuru Komahashi, Mitsuru Komahashi, Mitsuru Komahashi, Haruhiro Saito, Koichi Azuma, Tetsuro Sasada, Tetsuro Sasada

Get full text